Kanavape: the 3 main implications of the European verdict for France
Last Thursday, the Court of Justice of the European Union (CJEU) handed down its verdict in the Kanavape case. The lawsuit filed by French authorities to ban the sale of a CBD e-cigarette ultimately led to a European clarification of the law regarding CBD; here are the three main implications for France.
CBD is not a narcotic
In its ruling of November 19, the European court therefore ruled that the CBD «cannot be considered a narcotic» because, «according to the current state of scientific knowledge,» this molecule has «no psychotropic effects and no harmful effects on human health.».
In particular, by conducting a thorough and rigorous reading of the 1961 Convention, the CJEU concurs here with the opinion of the World Health Organization, who called for CBD to be removed from international conventions, or the World Anti-Doping Agency, who removed CBD from the list of banned substances. Recently, the United Kingdom and theItaly had also officially refused to classify CBD as a narcotic.
A Member State may not restrict the free movement of CBD-based products
This previous conclusion has a direct consequence: it is impossible to apply any regime to CBD other than the European Union’s rules on the free movement of goods. France cannot, therefore, block the entry into its territory of CBD or products containing it.
Direct consequence for the CBD stores : They will now be able to legally sell CBD-containing products if the CBD—or the finished product—comes from abroad.
The ruling does not directly apply to hemp flowers whose status remains unchanged.
CBD can be derived from hemp flowers
The CJEU ruling also addresses the French position which would consider synthetic CBD legal but not natural CBD—or, if it were, only if it is derived from seeds and fibers. CBD is therefore legal even if it «is extracted from the entire Cannabis sativa [hemp] plant and not solely from its fibers and seeds.».
At the European level, CBD derived from flowers will thus also be permitted for use in cosmetics, which, for the time being, limited the source of CBD to cannabis leaves.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in France3 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption
-
Cannabis in Spain4 weeks ago
Spain: Medical Cannabis Is Coming to About 50 Hospitals
-
Business4 weeks ago
British patients now have access to THCV-rich cannabis flowers
-
Cannabis in Canada3 weeks ago
A Canadian study reveals the pleasant psychotropic effects of high-dose CBD


You must be logged in to post a comment Login